Abbott
32,175.00
-400.00(-1.23%)
Market Cap₹69,219.60 Cr
PE Ratio47.71
IndustryHealthcare
Company Performance:
1D-1.23%
1M-5.35%
6M+2.01%
1Y+8.20%
5Y+94.51%
View Company Insightsright
More news about Abbott
04Aug 25
ABB India Q2 Results: Revenue Grows 12% Amid Margin Pressure
ABB India's Q2 results show a 12% revenue growth to ₹3,175.00 crore, meeting expectations. However, profitability declined with EBITDA falling 24% to ₹414.90 crore and net profit decreasing by 21% year-on-year. EBITDA margin dropped to 13% from 19.2%. The company faced significant cost increases across various categories, including a 26% rise in raw material costs. Order inflow declined by 12% to ₹3,036.00 crore, but the order book grew 6% annually, crossing ₹10,000.00 crore. The board approved evaluating the potential incorporation of the Robotics division into a wholly-owned subsidiary. ABB India's stock closed 2.3% lower at ₹5,384.00 following the results.
02Aug 25
ABB India Q2 Profit Drops 21%, Revenue Grows Amid Margin Pressure
ABB India's Q2 financial results show a 12.2% year-over-year revenue increase to Rs 3,175.00 crore, beating estimates. However, net profit fell 21% to Rs 352.00 crore, missing analyst expectations. EBITDA decreased 23.7% to Rs 414.00 crore, with margins contracting from 19.2% to 13.00%. The company declared an interim dividend of Rs 9.77 per share. Despite challenges, 18 out of 31 analysts maintain a 'Buy' rating on the stock.
01Aug 25
Abbott India Pays Rs. 2 Lakh Penalty to RBI for Exceeding Foreign Investment Limits
Abbott India Limited has been penalized Rs. 2 lakh by the Reserve Bank of India for violating foreign exchange laws. The violation occurred when foreign investment in the company exceeded 75% without prior government approval. The RBI issued a Compounding Order on July 31, 2025, concluding the compounding process. Abbott India will deposit the penalty amount and can now receive foreign institutional investments up to the prescribed limit.
16May 25
Abbott India's Q4 Profit Surges, Beats Estimates
Abbott India Ltd reported strong Q4 financial results, surpassing market expectations. Net profit increased by 14.7% to ₹359.00 crore, revenue rose by 9% to ₹1,633.00 crore, and EBITDA grew by 15% to ₹439.00 crore. The company's stock gained nearly 4% following the announcement, reaching ₹31,500.00 per share.
15May 25
Abbott India: Q4 Profit Soars 28%, ₹475 Dividend Proposed
Abbott India's Q4 results show strong growth with net profit up 27.90% to ₹367.00 crore, revenue increasing 11.50% to ₹1,604.60 crore, and EBITDA rising 30.00% with margin expansion to 26.70%. The company has recommended a final dividend of ₹475.00 per share, subject to shareholder approval.
Abbott
32,175.00
-400.00
(-1.23%)
1 Year Returns:+8.20%
Industry Peers
Sun Pharmaceutical
1,582.30
(+0.23%)
Divis Laboratories
6,133.50
(-0.49%)
Cipla
1,577.80
(-0.04%)
Torrent Pharmaceuticals
3,599.30
(-0.21%)
Mankind Pharma
2,568.90
(+0.38%)
Dr Reddys Laboratories
1,253.00
(-0.73%)
Zydus Life Science
1,011.95
(+0.37%)
Lupin
1,939.20
(-0.61%)
Abbott
32,175.00
(-1.23%)
Alkem Laboratories
5,301.50
(+0.18%)